Man Group PLC has disclosed an interest in 2.6% of DCC plc's ordinary shares, including direct ownership and derivatives, as per the Irish Takeover Panel rules. This disclosure signals a significant stake ahead of any potential takeover activity involving DCC plc. The detailed report includes recent sales and derivative transactions by Man Group, reflecting adjustments in their position. Such disclosures are important for market transparency and may influence investor decisions regarding DCC plc.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
A KAYAK survey of 2,000 Brazilian travelers revealed Cristiano Ronaldo as the most desired football companion for trips, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9%, respectively. The Northeast region of Brazil,...
A KAYAK survey of 2,000 Brazilian travelers found Cristiano Ronaldo is the most desired football player to travel with, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9% respectively. Most Brazilians (59%) would take ...
Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and e...
Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. Th...
